106
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Incidence of and risk factors for symptomatic benign prostatic hyperplasia in kidney transplant recipients: A cohort study

, , , , &
Pages 290-294 | Received 17 Jun 2012, Accepted 26 Sep 2012, Published online: 25 Oct 2012

References

  • Singh N, Nori U, Pesavento T. Kidney transplantation in the elderly. Curr Opin Organ Transplant 2009;14:380–5.
  • Hurst FP, Neff RT, Falta EM, Jindal RM, Lentine KL, Swanson JS, et al. Incidence, predictors, and associated outcome of prostatism after kidney transplantation. Clin J Am Soc Nephrol 2009;4:329–36.
  • Rule AD, Lieber MM, Jacobsen SJ. Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol 2005;173:691–6.
  • Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008;102:981–6.
  • Jacobsen SJ. Risk factors for benign prostatic hyperplasia. Curr Urol Rep 2007;8:281–8.
  • Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, et al. Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol 2006;100:24–33.
  • Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 2008;9:272–8.
  • Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology 2008;72:247–54.
  • Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233–44.
  • Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006;29:305–14.
  • Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16:133–43.
  • Ali RB, Klouz A, Boubaker S, Lakhal M, Belkahia C. An animal model of testicular toxicity by cyclosporine: evaluation and protection. Fundam Clin Pharmacol 2009;23:241–6.
  • Lopez-Barcons LA. Human benign prostatic hyperplasia heterotransplants as an experimental model. Asian J Androl 2010;12:157–63.
  • Koziolek MJ, Wolfram M, Müller GA, Scheel AK, Strutz F, Scheuermann EH, et al. Benign prostatic hyperplasia (BPH) requiring transurethral resection in freshly transplanted renal allograft recipients. Clin Nephrol 2004;62:8–13.
  • Tsaur I, Jones J, Melamed RJ, Blaheta RA, Gossmann J, Bentas W. Postoperative voiding dysfunction in older male renal transplant recipients. Transplant Proc 2009;41:1615–18.
  • Zhang Y, Wang Y, Zhang P, Zhang XD, Yang Y. Extended-release doxazosin for treatment of renal transplant recipients with benign prostatic hyperplasia. Transplant Proc 2009;41:3747–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.